AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04008732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MED2005
Description: (Day -1 to Day 1): Subjects will undergo six treatment periods, each separated by at least a two day washout. Each treatment period will be approximately 1 day in duration from the afternoon of Day -1 to the afternoon of Day 1 at 6 hours (h) post-dose. In each of the treatment periods, the subject will receive one of the six administrations over 6 treatment periods (1/period) and will return approximately two days later for the next treatment period.
Study NCT04008732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MED2005
Description: (Day -1 to Day 1): Subjects will undergo six treatment periods, each separated by at least a two day washout. Each treatment period will be approximately 1 day in duration from the afternoon of Day -1 to the afternoon of Day 1 at 6 hours (h) post-dose. In each of the treatment periods, the subject will receive one of the six administrations over 6 treatment periods (1/period) and will return approximately two days later for the next treatment period.
Study NCT04008732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitrostat 0.6Mg Sublingual Tablet
Description: Active comparator to be used for Part 1 of the study. Nitrostat will be dosed in two treatment periods and 3 x 0.6 mg tablets will be required to make up the 1.8 mg dose.
Study NCT04008732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrostat 0.6Mg Sublingual Tablet
Description: Active comparator to be used for Part 1 of the study. Nitrostat will be dosed in two treatment periods and 3 x 0.6 mg tablets will be required to make up the 1.8 mg dose.
Study NCT04008732 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitro Pohl
Description: to be dosed intravenously in Part 2 of the study
Study NCT04008732 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitro Pohl
Description: to be dosed intravenously in Part 2 of the study
Study NCT01338467 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EYEOP device
Description: Cyclocoagulation using High Intensity Focused Ultrasound with EYEOP device
Study NCT01290627 — intervention group
Intervention type: DEVICE
Intervention: Subjects implanted with DePuy LCS PS RP TKA
Description: Subjects implanted with DePuy Low Contact Stress (LCS) Poster Stabilizing (PS) Rotating Platform (RP) Total Knee Arthroplasty (TKA)
Study NCT01290627 — intervention group
Intervention type: DEVICE
Intervention: Subjects implanted with DePuy Sigma PS RP TKA
Description: Subjects implanted with a DePuy Sigma Posterior Stabilizing (PS) Rotating Platform (RP) Total Knee Arthroplasty (TKA)
Study NCT00119678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abatacept
Description: Injectable, intravenous, 10 mg/kg, abatacept every 28 days, 12 months
Study NCT00119678 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Injectable, intravenous, 0 mg, every 28 days, 12 months
Study NCT00119678 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Tablets, oral, 30 mg, daily for 28 days then taper off, 12 months
Study NCT03014960 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Online Cognitive Behavioral Therapy for Insomnia (CBT-I)
Description: CBT-I is a psychological treatment designed to break the patterns of maladaptive thinking and behavior that maintain insomnia. CBT-I includes a range of techniques including a behavioral component (stimulus control, sleep restriction, relaxation) combined with a cognitive component (managing sleep related worries, the racing mind and intrusive thoughts) and an educational (sleep hygiene) component.
Study NCT02080052 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robot-assisted prostate biopsy
Study NCT01631669 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 200 mg Q 12 hours orally
Study NCT03556215 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eustachian tube dilatation device
Description: Balloon Eustachian tuboplasty will be performed using a Eustachian tube dilatation device.
Study NCT00119678 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Prednisone
Description: Tablets, oral, 30 mg, daily for 28 days then taper off, 12 months
Study NCT00119678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Injectable, intravenous, 10 mg/kg, every 28 days
Study NCT04195555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib
Description: Given PO
Study NCT04327375 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Observational
Study NCT02100228 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: Oral, 2.5 or 5 mg BID
Study NCT04335305 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: IV infusion over 60 minutes; 8 mg/kg (up to a maximum of 800 mg per dose); single dose
Study NCT04335305 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab (MK-3475)
Description: IV infusion over 30 minutes, 200 mg; single dose
Study NCT00907452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: melphalan-prednisone-thalidomide
Study NCT00907452 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lenalidomide-dexamethasone
Study NCT02319629 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: URSODIOL
Description: preventive treatment with Ursolit to reduce the incidence of gallstones formation after bariatric surgery
Study NCT02100228 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Parenteral heparin and/or oral Vitamin K antagonist
Description: Parenteral heparin and/or locally used oral Vitamin K antagonist e.g. warfarin (excludes other novel oral anticoagulants)
Study NCT04484545 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Prognostic score
Description: Validation of scores of systemic inflammatory response
Study NCT01964092 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support
Study NCT01964092 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Ordinary employment schemes
Study NCT03120117 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cough Test following Sling Surgery
Description: Enrolled subjects will undergo sling surgery who present with stress-dominated urinary incontinence. While in the operating room, the subject will be asked to stand and cough to determine if there is still leakage once the sling has been placed.
Study NCT00580840 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Certolizumab pegol
Description: 200 mg certolizumab pegol and placebo administered every 2 weeks (one injection of each)
Study NCT03556215 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Myringotomy
Description: Myringotomy will be performed using a standard procedure.
Study NCT00580840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo (saline) administered as two injections every 2 weeks
Study NCT00580840 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: placebo (saline) administered as two injections every 2 weeks
Study NCT00580840 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo (saline) administered as two injections every 2 weeks
Study NCT02659904 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Less than 2 mm remaining palatal tissue thickness
Description: The greater palatine and incisive nerves were blocked with 2% lidocaine, 1:100,000 epinephrine injection. After preparation of the recipient bed, free gingival graft was harvested using a handle with knife at palatal donor side with acrylic stent guidance.
Study NCT02659904 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 2 mm or more remaining palatal tissue thickness
Description: The greater palatine and incisive nerves were blocked with 2% lidocaine, 1:100,000 epinephrine injection. After preparation of the recipient bed, free gingival graft was harvested using a handle with knife at palatal donor side with acrylic stent guidance.
Study NCT00107497 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiation therapy
Study NCT00830232 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: closed-cell stent (Xact stent)
Description: Patients enrolled in this study arm underwent for carotid stenting using closed stent cell. The graft used in this groups was the Xact closed-cell stent. This type of device is rigid device with dense conposition of the nitinol rigns.~Carotid stenting was used on standard fashion using filters as embolic protection device.
Study NCT00830232 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Open-cell stent (Acculink carotid)
Description: Patients enrolled in this study arm underwent for carotid stenting using open stent cell stents. This type of stent is a tube shaped graft composed of flexible nitinol rings. The device used in this group was the Acculinx open-cell stent.~Stenting procedure eas performed on standard fashion.Filters were used as embolic protection device.
Study NCT00757809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neratinib
Description: HKI-272
Study NCT01821144 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Salt reduction
Description: Salt reduction
Study NCT01821144 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: No salt awareness education
Study NCT03992066 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: oral 150 mg tablet
Study NCT03992066 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Darbepoetin alfa
Description: solution intravenous injection
Study NCT03992066 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Epoetin alfa
Description: solution for intravenous injection
Study NCT02501005 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VT ablation
Description: Catheter ablation of ventricular tachycardia
Study NCT02501005 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: VT ablation
Description: Catheter ablation of ventricular tachycardia
Study NCT02815319 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Steroid prophylaxis
Study NCT01840046 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: The patient will receive 4 cycles of recombinant interleukin 2 (aldesleukin, Proleukin ®) subcutaneously according to the following dosing schedule:~5 to 7 days (Monday to Friday) in weeks 1, 3, 6 and 9.~The dosage is as follows:~S1: 1.5 mille-International unit / day (D1 to D5), S3, S6 and S9: 3 mille-International unit /Jour (D1 to D5).
Study NCT01893567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clobex Spray
Study NCT00803491 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Problem based learning
Description: Group sessions under supervision from a nurse. Each group including 8 subjects. 10 occasions during a period of one year.
Study NCT00803491 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional rheumatology care.
Description: Individually base.
Study NCT04626856 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dosage IRV on a 0- and 28-day schedule
Description: Inactivated Rotavirus vaccine (Vero cell) of 80EU/0.5ml on day 0, 28
Study NCT04626856 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medium dosage IRV on a 0- and 28-day schedule
Description: Inactivated Rotavirus vaccine (Vero cell) of 160EU/0.5ml on day 0, 28
Study NCT04626856 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dosage IRV on a 0- and 28-day schedule
Description: Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on day 0,28
Study NCT04626856 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dosage IRV on a 0- and 28-day schedule
Description: Inactivated Rotavirus vaccine (Vero cell) of 80EU/0.5ml on day 0,28
Study NCT04626856 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medium dosage IRV on a 0- and 28-day schedule
Description: Inactivated Rotavirus vaccine (Vero cell) of 160EU/0.5ml on day 0,28
Study NCT04626856 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dosage IRV on a 0- , 28- and 56-day schedule
Description: Inactivated Rotavirus vaccine (Vero cell) of 80EU/0.5ml on day 0,28,56
Study NCT04626856 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medium dosage IRV on a 0- , 28- and 56-day schedule
Description: Inactivated Rotavirus vaccine (Vero cell) of 160EU/0.5ml on day 0,28,56
Study NCT04626856 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dosage IRV on a 0- , 28- and 56-day schedule
Description: Inactivated Rotavirus vaccine (Vero cell) of 320EU/0.5ml on day 0,28,56
Study NCT04626856 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo on day 0, 28
Description: Two doses of placebo at the vaccination schedule of day 0,28
Study NCT04626856 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo on day 0, 28, 56
Description: Three doses of placebo at the vaccination schedule of day 0, 28,56
Study NCT03981341 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duavive (0.45 estrogens mg and 20 mg bazedoxifene)
Description: Drug given for 3 months in each participant
Study NCT02965326 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Nasal swab; rectal biopsy.
Description: Nasal epithelial cells will be obtained by nasal swabs from patients of the three arms; intestinal epithelial cells will be obtained, by rectal biopsy, only from patients treated by CFTR modulators.
Study NCT03456947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: the patients receive 150mg or 300mg pregabalin 60 minutes prior to the surgery
Study NCT03169205 — intervention group
Intervention type: OTHER
Intervention: observation registry
Description: observation registry
Study NCT02155205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telotristat etiprate
Description: 1500 mg telotristat etiprate (six 250 mg tablets)
Study NCT02155205 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo
Study NCT02155205 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: 400 mg moxifloxacin (one 400 mg tablet)
Study NCT03370549 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AWARE intervention
Description: Group psychotherapy for Asian-American women
Study NCT03370549 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: AWARE intervention
Description: Group psychotherapy for Asian-American women
Study NCT04462926 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: [68Ga]Ga-PSMA-11 PET/CT
Description: 1.8-2.2 MBq (0.049-0.060 mCi) per kilogram bodyweight will be injected intravenously prior to perform the PET/CT
Study NCT00841178 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Saphenopopliteal junction ligation, stripping of the Short Saphenous vein where possible, perforator ligation and ambulatory phlebectomy, where necessary.
Study NCT00841178 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EVLT
Description: EVLT of the Short saphenous vein with perforator ligation and / or ambulatory phlebectomy as required.
Study NCT00992771 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: varenicline
Description: up to 1mg BID for 8 weeks
Study NCT00992771 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo matching varenicline, up to 1mg BID for 8 weeks
Study NCT02335840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAF-1
Description: In this intervention the volunteers ingested one dose of caffeinated coffee containing 144 mg of caffeine
Study NCT02335840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAF-2
Description: In this intervention the volunteers ingested two doses of caffeinated coffee containing 288 mg of caffeine
Study NCT02335840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CAF-3
Description: In this intervention the volunteers ingested three doses of caffeinated coffee containing 432mg of caffeine
Study NCT02335840 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: DESC
Description: In this intervention the volunteers ingested one dose of decaffeinated coffee containing 108 mg of caffeine
Study NCT02458469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Buspirone
Description: The initial dose of Buspirone is 15 mg daily (7.5 mg bid.). To achieve an optimal therapeutic response, at intervals of 2 to 3 days the dosage may be increased 5 mg per day until a maximum dose 30mg/day is reached.
Study NCT02458469 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trazodone
Description: 100 mg dose before bed-time
Study NCT02458469 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One placebo pill before bed-time
Study NCT03613922 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Manual Therapy
Description: Mulligan's Mobilization with Movement technique for radiocarpal,ulnocarpal, distal radioulnar and proximal radioulnar joints was applied.
Study NCT04056026 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fecal Microbiota Transplant
Description: Fecal material from a healthy family donor will be transplanted into the patient via colonoscopy
Study NCT00208975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mitoxantrone/Cyclophosphamide, Fludarabine, Rituximab and GM-CSF
Description: Initial patients (n=9) received fludarabine (25 mg/m\^2 intravenously) and mitoxantrone (10 mg/m\^2 intravenously)with sequential administration of GM-CSF(Granulocyte-macrophage colony stimulating factor) (500 µcg subcutaneously) on days 6 and 7 and rituximab (375 mg/m\^2) on day 8.~After a change in the protocol, all additional patients (n=6) received fludarabine (25 mg/m\^2 intravenously) and cyclophosphamide (250 mg/m\^2 intravenously)with sequential administration of GM-CSF (500 µcg subcutaneously) on days 6 and 7 and rituximab (375 mg/m\^2) on day 8. All patients received additional doses of GM-CSF (days +8 through +14) were given for patients to reduce variability in neutropenic management.
Study NCT01777724 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combination of Triple P Discussion Groups and Stress Control
Description: The intervention consists of eight group sessions: two 120 minute Triple P Discussion Group sessions (http://www.triplep.net/), and six 90 minute Stress Control sessions (http://glasgowsteps.com/home.php).
Study NCT04244539 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: high-intensity laser Device.
Description: Twenty four treatment sessions with pulsed Nd: YAG laser were applied to the subjects of the study group, three sessions per week, over 8 weeks in succession via HIRO® 3.0 device (ASAlaser, Arcugnano, Vicenza, Italy). The device gives pulsed emission (λ = 1064 nm), maximum power (3000 W), fluency range (360-1780 mJ/cm2), pulse duration (≤ 100 μs), frequency range (10-40 Hz), maximum energy per pulse (350 mJ), mean power (10.5 W), and power cycle of \~0.1%.
Study NCT01008345 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezetimibe
Description: Patients will receive 10 mg/day of ezetimibe for 8 weeks
Study NCT01008345 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ezetimibe
Description: Patients will receive 10 mg/day of ezetimibe for 8 weeks
Study NCT03691415 — intervention group
Intervention type: DRUG
Intervention: BELKYRA Inj.
Description: Patient will be administered BELKYRA Inj. at least once and the interval between treatments not less than 1 month apart.
Study NCT01824979 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP mask ( Pilairo)
Study NCT01824979 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Other CPAP mask
Study NCT03720457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human CD19 targeted T Cells Injection
Description: Autologous genetically modified anti-CD19 CAR transduced T cells
Study NCT04336163 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Optical Coherence Tomography
Description: Skin imaging to determine vascular characteristics such as plexus depth, vessel diameter, and vessel density.
Study NCT04336163 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optical Coherence Tomography
Description: Skin imaging to determine vascular characteristics such as plexus depth, vessel diameter, and vessel density.
Study NCT03573167 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: In-Person Motivational Interviewing (MI)
Description: This is a counseling intervention to support behavior change conducted in-person (face-to-face) between the investigator and the participant.
Study NCT03573167 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Motivational Interviewing (MI)
Description: This is a counseling intervention to support behavior change conducted entirely over the mobile phone between the investigator and the participant
Study NCT03728881 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Quadrivalent Human Papillomavirus (types 6, 11, 16, 18) Recombinant Vaccine
Description: Given IM